Renal Cancer - Results from #1380

Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism. August 1, 2022

A Cluster of Metabolic-Related Genes Serve as Potential Prognostic Biomarkers for Renal Cell Carcinoma. July 29, 2022

Identifying an Immune-Related Gene ST8SIA1 as a Novel Target in Patients With Clear-Cell Renal Cell Carcinoma. July 29, 2022

Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma. July 28, 2022

Assessing the impact of socio-economic determinants on access to care, surgical treatment options and outcomes among patients with renal mass: Insight from the universal healthcare system. July 28, 2022

Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC). July 27, 2022

Impact of Worsening CKD-S in Preoperative CKD-naive Patients on Survival in Renal Cell Carcinoma. July 27, 2022

Protocol for the Flinders Kidney Health Registry: patient outcomes of kidney cancers and nephrectomies. July 26, 2022

GRAMD1A Is a Biomarker of Kidney Renal Clear Cell Carcinoma and Is Associated with Immune Infiltration in the Tumour Microenvironment. July 26, 2022

Comparison of perioperative outcomes following transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: a propensity-matched analysis of VCQI database. July 25, 2022

Systematic Investigation of Immune-Related lncRNA Landscape Reveals a Potential Long Non-Coding RNA Signature for Predicting Prognosis in Renal Cell Carcinoma. July 25, 2022

Analysis of Pyroptosis-Related Immune Signatures and Identification of Pyroptosis-Related LncRNA Prognostic Signature in Clear Cell Renal Cell Carcinoma. July 22, 2022

Association Between Metabolic Syndrome and Risk of Renal Cell Cancer: A Meta-Analysis. July 22, 2022

The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. July 21, 2022

Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. July 21, 2022

Development of a Novel Sphingolipid Signaling Pathway-Related Risk Assessment Model to Predict Prognosis in Kidney Renal Clear Cell Carcinoma. July 20, 2022

Tivozanib for the treatment of advanced renal cell carcinoma. July 20, 2022

In the Phase III IMmotion151 Trial of Metastatic Renal Cell Carcinoma the Easy-to-Implement Modified Glasgow Prognostic Score Predicts Outcome More Accurately than the IMDC Score July 19, 2022

Identification of Survival Risk and Immune-Related Characteristics of Kidney Renal Clear Cell Carcinoma. July 19, 2022

A novel nomogram can predict pathological T3a upstaged from clinical T1a in localized renal cell carcinoma. July 19, 2022

Page 70 of 456